Welcome to our dedicated page for ELIXINOL WELLNESS news (Ticker: ELLXF), a resource for investors and traders seeking the latest updates and insights on ELIXINOL WELLNESS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ELIXINOL WELLNESS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ELIXINOL WELLNESS's position in the market.
Elixinol has launched two innovative CBD products aimed at improving sleep: Sleep Rapid Rest Liposome and Sleep Gummies. The Sleep Rapid Rest Liposome combines CBD and CBN with natural ingredients like lemon balm and chamomile, available in two dosages priced at $59.99 for 300mg and $149.99 for 1000mg. The Sleep Gummies contain 15mg of CBD and 2mg of CBN, retailing at $29.99. This launch supports Elixinol's commitment to innovation in the CBD market, particularly in the growing sleep category. The products are backed by rigorous third-party testing and meet strict quality standards.
California recently passed Assembly Bill 45, establishing a regulatory framework for hemp-derived CBD products, significantly benefiting Elixinol, a leading provider in the CBD market. This bill, signed into law on October 6, 2021, aims to enhance product standards and compliance, aligning with Elixinol's e-commerce strategy as California accounts for 14% of its online revenue. Coinciding with this, Elixinol launched an upgraded online shop to boost user experience and sales potential. Additionally, the appointment of the Market Performance Group will facilitate access to major retail channels.
Elixinol has launched its first line of CBD pet products aimed at improving the wellness of dogs. The collection includes a bacon-flavored tincture and two functional CBD dog chews designed for specific health benefits. The products are rigorously tested and certified for quality. The Elixinol pet collection features Everyday Dog Drops, Calm Dog Chews, and Active Mobility Dog Chews, each containing specific ingredients to support various aspects of canine health. The new line is now available on Elixinol.com.
Elixinol Wellness Limited (ELLXF) announced the appointments of Rob Hasselman as President Americas and Beata Silber as Global Head of R&D and Innovation. These strategic hires aim to enhance the company's transformation into a global wellness business, fostering revenue growth and profitability. Rob brings over 27 years of healthcare experience, while Beata has 20 years in clinical research and product development. CEO Oliver Horn emphasized the appointments as vital for Elixinol's competitive advantage and product innovation in the CBD sector.
Elixinol has launched Immune Gut Health, the first CBD capsules infused with Ginfort™, a proprietary ingredient clinically tested for digestion support. Each capsule offers 15mg of CBD and 200mg of Ginfort™, which boasts 13 times more ginger actives than standard ginger powders. The product is designed to enhance immune system health, leveraging the synergy between ginger's gut health benefits and CBD's effects on the body's CB2 receptors. Available for $64.99 for a 60-count bottle, it is exclusively sold on Elixinol.com. This product represents a significant addition to Elixinol's immunity-focused product line.
The UK Food Standards Agency (FSA) has confirmed that Elixinol's products comply with the novel food application requirements, allowing continued sales in the UK. This notification follows an earlier deadline set for CBD firms to submit their applications by March 31, 2021. Elixinol's membership in the EIHA's Novel Food Consortium ensures support for their products under this application. The FSA will grant official validation once ongoing toxicological studies on CBD and THC are completed, expected in the coming months. This positions Elixinol to explore new customer contract opportunities.
Elixinol Global Limited (OTCQB:ELLXF) has announced a binding agreement for its subsidiary to acquire CannaCare Health GmbH, a leading German CBD brand with a significant market share. The upfront consideration will be €9 million, including €3 million in cash and €6 million in shares, with a potential maximum earn-out of €15 million based on future performance. This acquisition positions Elixinol for accelerated growth in the European CBD market, projected to grow at a CAGR of 47%. Elixinol will discuss the acquisition at the Cannabis Investing Forum on March 18.
Elixinol Global (ASX:EXL, OTC PINK:ELLXF) announces participation in the SNN Network Australia Virtual Event on November 10, 2020, at 5 PM PDT. Group CEO Oliver Horn will present the Q3 FY2020 results, showcasing an 18% revenue growth quarter-on-quarter and discuss future growth strategies. Horn expressed optimism about the cannabis and CBD industries following recent elections in the U.S. For details, register at SNN Network. The full agenda is accessible at Agenda.
FAQ
What is the market cap of ELIXINOL WELLNESS (ELLXF)?
